Biohaven stock hurdled its 50-day and 200-day lines Tuesday after the FDA granted its SCA treatment a speedier review time.
ALS candidates from Biohaven, Prilenia, Clene and UCB have all failed to halt disease progression versus placebo in the ...
Biohaven boasts a robust pipeline with late-stage molecules, but a Hold rating reflects its high market cap and uncertain ...
News of a big and important regulator's move was the electricity that powered Biohaven (NYSE: BHVN) stock to an 11%-plus gain ...
Biohaven (BHVN) is jumping 10% after the FDA agreed to review the company’s potential treatment for a rare disease. The FDA’s ...
Troriluzole has a well-established safety profile and if approved, would be the first and only FDA-approved treatment for SCA; subject to receipt of FDA approval, Biohaven is prepared to ...
Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...
Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of ...
Spire Wealth Management bought a new position in shares of Biohaven Ltd. (NYSE:BHVN – Free Report) during the 4th quarter, ...
Deutsche Bank initiated coverage of Biohaven (BHVN) with a Buy rating and $65 price target Maximize Your Portfolio with Data Driven ...
In trading on Tuesday, shares of Biohaven Ltd (Symbol: BHVN) crossed above their 200 day moving average of $40.76, changing hands as high as $42.68 per share. Biohaven Ltd shares are currently ...
Approval could come rather soon. Before market open, Biohaven announced that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for troriluzole. This is a once ...